Nextcure Stock Performance

NXTC Stock  USD 13.37  0.22  1.62%   
NextCure holds a performance score of 13 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.78, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NextCure's returns are expected to increase less than the market. However, during the bear market, the loss of holding NextCure is expected to be smaller as well. Use NextCure semi variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on NextCure.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in NextCure are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, NextCure exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
(1.62)
Five Day Return
(0.96)
Year To Date Return
0.68
Ten Year Return
(94.40)
All Time Return
(94.40)
Last Split Factor
1:12
Last Split Date
2025-07-14
1
Quantitative breakdown of NextCure Inc. recent move - Portfolio Value Summary Accurate Buy Signal Alerts - newser.com
10/14/2025
2
How NextCure Inc. stock reacts to inflationary pressures - 2025 Breakouts Breakdowns Low Risk High Win Rate Picks - newser.com
10/29/2025
3
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
11/05/2025
4
Does NextCure Have the Potential to Rally 107.88 percent as Wall Street Analysts Expect
11/11/2025
5
How NextCure Inc. stock reacts to inflationary pressures - Trade Signal Summary Risk Adjusted Buy and Sell Alerts - newser.com
11/14/2025
6
How currency fluctuations impact NextCure Inc. stock - Portfolio Risk Report AI Driven Price Forecasts - newser.com
11/19/2025
7
NextCure files for offering of up to 2.52 million shares of common stock by selling stockholders - SEC filing - MarketScreener
11/26/2025
8
NextCure Stock Rating Upgraded by Wall Street Zen
12/15/2025
9
Will NextCure Inc. stock remain a Wall Street favorite - Stop Loss Expert Verified Stock Movement Alerts - ulpravda.ru
01/08/2026
Begin Period Cash Flow13.1 M
Total Cashflows From Investing Activities55.3 M

NextCure Relative Risk vs. Return Landscape

If you would invest  635.00  in NextCure on October 12, 2025 and sell it today you would earn a total of  702.00  from holding NextCure or generate 110.55% return on investment over 90 days. NextCure is currently generating 1.644% in daily expected returns and assumes 9.7629% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of stocks are less volatile than NextCure, and 67% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days NextCure is expected to generate 13.89 times more return on investment than the market. However, the company is 13.89 times more volatile than its market benchmark. It trades about 0.17 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of risk.

NextCure Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for NextCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NextCure, and traders can use it to determine the average amount a NextCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1684

High ReturnsBest Equity
Good Returns
Average ReturnsNXTC
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns
Based on monthly moving average NextCure is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NextCure by adding it to a well-diversified portfolio.

NextCure Fundamentals Growth

NextCure Stock prices reflect investors' perceptions of the future prospects and financial health of NextCure, and NextCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NextCure Stock performance.

About NextCure Performance

By analyzing NextCure's fundamental ratios, stakeholders can gain valuable insights into NextCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NextCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NextCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand(51.33)(53.89)
Return On Tangible Assets(0.79)(0.83)
Return On Capital Employed(0.96)(1.01)
Return On Assets(0.79)(0.83)
Return On Equity(0.98)(0.93)

Things to note about NextCure performance evaluation

Checking the ongoing alerts about NextCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NextCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
NextCure is way too risky over 90 days horizon
NextCure appears to be risky and price may revert if volatility continues
NextCure has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (55.65 M) with loss before overhead, payroll, taxes, and interest of (54.2 M).
NextCure currently holds about 185.49 M in cash with (40.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68.
NextCure has a frail financial position based on the latest SEC disclosures
Roughly 20.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: Will NextCure Inc. stock remain a Wall Street favorite - Stop Loss Expert Verified Stock Movement Alerts - ulpravda.ru
Evaluating NextCure's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate NextCure's stock performance include:
  • Analyzing NextCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NextCure's stock is overvalued or undervalued compared to its peers.
  • Examining NextCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating NextCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NextCure's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of NextCure's stock. These opinions can provide insight into NextCure's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating NextCure's stock performance is not an exact science, and many factors can impact NextCure's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for NextCure Stock analysis

When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon